Iterum Therapeutics (ITRM)
NASDAQ: ITRM
· Real-Time Price · USD
0.97
-0.00 (-0.47%)
At close: Jul 02, 2025, 3:59 PM
0.97
0.12%
After-hours: Jul 02, 2025, 07:48 PM EDT
-0.47% (1D)
| Bid | 0.96 |
| Market Cap | 38.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -22.56M |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | -1.03 |
| Forward PE | -14.14 |
| Analyst | Buy |
| Ask | 1.1 |
| Volume | 434,598 |
| Avg. Volume (20D) | 528,708 |
| Open | 0.98 |
| Previous Close | 0.97 |
| Day's Range | 0.95 - 0.98 |
| 52-Week Range | 0.81 - 3.02 |
| Beta | 2.82 |
About ITRM
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ITRM
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ITRM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
-15.87%
Iterum Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
8 months ago
+60.68%
Iterum Therapeutics shares are trading higher after the FDA approved the company's new drug application for ORLYNVAH for the treatment of uncomplicated urinary tract infections.
